What if cancer treatment could work by helping your own immune system recognise and attack cancer cells?
That is the principle behind immunotherapy for cancer, an important area of modern oncology. Unlike conventional treatments that directly target cancer cells, immunotherapy works by strengthening or directing parts of the immune response against them.
But immunotherapy is not suitable for every patient or every type of cancer. The decision depends on the cancer, its stage, specific biomarkers, previous treatment and the patient's overall health.
Before recommending immunotherapy treatment, an oncologist may consider:
- Cancer type and stage: Some cancers have stronger evidence for immunotherapy than others.
- Biomarker results: Tests such as PD-L1, MSI or other molecular markers may help guide treatment.
- Overall health: Existing medical conditions and previous treatments can influence suitability.
Understanding these factors can help patients approach an immunotherapy consultation with greater clarity.
What Is Immunotherapy and How Does It Work?
The immune system is naturally designed to identify and respond to abnormal cells. Cancer cells, however, can develop ways to avoid immune detection or suppress the immune response.
Cancer immunotherapy treatment aims to overcome some of these barriers. Depending on the medicine, it may remove signals that hold immune cells back, direct immune cells towards cancer or strengthen specific parts of the immune response.
One of the most widely used approaches is immune checkpoint inhibition. Checkpoint proteins normally act like controls that prevent the immune system from becoming excessively active. Certain cancer cells can exploit these controls to avoid attack. Checkpoint inhibitors block these signals, allowing immune cells to respond more effectively.
What Are the Types of Immunotherapy?
There is no single form of immunotherapy. Different treatments work through different mechanisms and are used according to the cancer and individual clinical circumstances.
Common approaches include:
Immune checkpoint inhibitors
These medicines target proteins such as PD-1, PD-L1 or CTLA-4, helping immune cells recognise and attack cancer cells more effectively. They are used across several cancer types.
Monoclonal antibodies
These laboratory-made antibodies are designed to recognise specific targets. Some mark cancer cells so the immune system can identify them, while others influence immune pathways involved in cancer treatment.
T-cell therapies
In certain treatments, immune cells are collected and modified or selected so that they can better recognise cancer cells before being returned to the patient. CAR T-cell therapy is one example of this approach.
Immune system modulators and treatment vaccines
These approaches stimulate or modify immune activity in different ways and are used for selected cancers and clinical situations.
The choice depends on much more than the name of the cancer. The oncologist considers the available evidence, tumour characteristics and the patient's individual circumstances.
Who May Be Eligible for Immunotherapy?
A diagnosis of cancer does not automatically mean that immunotherapy is appropriate. Eligibility is assessed individually.
Doctors may look at:
- Tumour biology: Biomarker testing may identify characteristics associated with response to particular immunotherapies.
- Stage and treatment history: Immunotherapy may be used at different points, including alongside other treatments or when cancer has returned or spread.
- General health: Existing medical conditions, medications and previous treatments may affect the safety and suitability of a particular medicine.
For some patients, immunotherapy may be given alone. For others, it may be combined with chemotherapy, targeted therapy, surgery or radiotherapy.
This is why an oncology consultation is important before assuming that immunotherapy is either necessary or unsuitable.
What Are the Potential Benefits?
One of the most important immunotherapy benefits is that it can produce meaningful and sometimes long-lasting responses in certain cancers. However, responses vary, and immunotherapy does not work for everyone.
Its potential advantages include:
A different treatment mechanism
Rather than directly attacking cancer cells in the same way as chemotherapy, immunotherapy aims to engage the body's immune response.
Longer-lasting responses in some patients
Some people can experience sustained responses after treatment. The likelihood varies according to cancer type, treatment and individual tumour characteristics.
Combination possibilities
Immunotherapy can sometimes be combined with chemotherapy, targeted therapy or other treatments when clinical evidence supports the approach.
These benefits need to be weighed against the potential risks and the patient's specific treatment goals.
What Are the Risks and Side Effects?
Because immunotherapy activates or modifies the immune system, its side effects can differ from those associated with traditional chemotherapy.
Some patients may experience:
- Fatigue, fever or flu-like symptoms
- Skin rash or itching
- Nausea, vomiting or diarrhoea
- Muscle or joint discomfort
- Changes affecting hormone-producing glands
In some cases, the immune system can begin affecting healthy organs and tissues. This can lead to inflammation involving the bowel, lungs, liver, kidneys or other organs. These reactions can occasionally be serious.
Early reporting matters
Patients should not wait for a scheduled appointment if they develop a new or unusual symptom during treatment.
- Breathing changes: New breathlessness or persistent cough should be reported promptly.
- Digestive symptoms: Significant or persistent diarrhoea should be discussed with the oncology team.
- Unusual fatigue or hormonal symptoms: These can sometimes indicate changes that require assessment.
Side effects can occur during treatment and, in some cases, even after treatment has finished.
How Is Immunotherapy Given?
The method and schedule depend on the particular treatment. Many immunotherapies are given through an intravenous infusion in an outpatient setting, while some may be given by injection or other routes.
Treatment may be administered at regular intervals, such as every few weeks, depending on the medicine and cancer being treated.
| Factor | What it may depend on |
|---|---|
| Type of treatment | Cancer type and treatment objective |
| Frequency | Medicine and clinical protocol |
| Duration | Response and individual treatment plan |
| Monitoring | Blood tests, symptoms and clinical assessment |
| Combination | Whether another cancer treatment is recommended |
Before each treatment, the oncology team may review symptoms, blood results and overall health to determine whether treatment should proceed as planned.
Why Specialist Assessment Matters
Immunotherapy has expanded the options available in modern oncology, but it is not a universal replacement for chemotherapy, surgery or radiotherapy.
The most appropriate immune-based cancer treatment depends on evidence for that particular cancer and the patient's individual clinical profile. An experienced oncology team can assess pathology, scans, biomarker results and previous treatment before recommending an approach.
For patients looking for an immunotherapy centre Mumbai option, IOHC provides immunotherapy as part of its broader oncology services, with treatment recommended where clinically appropriate.
Take the Next Step With a Clear Treatment Plan
If immunotherapy has been suggested for you or someone close to you, understanding why it has been recommended is just as important as understanding how it is given. Ask about the treatment objective, relevant biomarkers, expected benefits, possible side effects and how your response will be monitored.
A specialist oncology consultation can help turn a complex treatment decision into a clear, individualised plan. If you are considering immunotherapy, speak with an experienced oncology team at the earliest opportunity to understand whether it is appropriate for your cancer and what other treatment options may need to be considered.
Frequently Asked Questions
Is immunotherapy suitable for everyone with cancer?
No. Immunotherapy treatment is appropriate for selected cancers and clinical situations. The decision depends on factors such as cancer type, stage, biomarkers and previous treatment.
Biomarkers: Certain tumour characteristics may help indicate whether a particular immunotherapy could be useful.
Overall health: Existing conditions and previous treatments are also considered.
Which cancers can be treated with immunotherapy?
Immunotherapy is used for several cancer types, but its role differs considerably between cancers. Cancer immunotherapy treatment may be used alone or alongside other treatments depending on the clinical situation.
Cancer biology: Biomarkers can influence whether immunotherapy is considered.
Treatment stage: It may be used before or after other treatments or for advanced cancer in selected cases.
Is immunotherapy better than chemotherapy?
They work differently, so one cannot simply be considered better than the other. Immune-based cancer treatment may be used alone, alongside chemotherapy or as part of another combination depending on the cancer.
Mechanism: Chemotherapy directly targets rapidly dividing cells, while immunotherapy helps the immune system respond against cancer.
Treatment plan: The choice depends on evidence, tumour characteristics and the patient's circumstances.
What are the common side effects of immunotherapy?
Common immunotherapy side effects can include fatigue, skin reactions, fever, nausea, diarrhoea and muscle or joint discomfort.
Immune-related effects: The immune system can sometimes affect healthy organs, causing inflammation.
Early attention: New or worsening symptoms should be reported promptly to the oncology team.
How long does immunotherapy treatment last?
There is no fixed duration for every patient. The length of immunotherapy treatment depends on the cancer, medicine being used, treatment response and overall health.
Treatment schedule: Some medicines are administered at regular intervals over several months.
Ongoing assessment: Doctors may review the treatment plan according to response and tolerability.
What tests are done before immunotherapy?
Doctors may review pathology, imaging, blood tests and relevant biomarkers before starting precision cancer treatment. The exact investigations depend on the cancer and proposed medicine.
Biomarker testing: Results such as PD-L1 or other molecular characteristics may influence treatment selection.
Baseline assessment: Blood and other investigations can help establish whether treatment can be given safely.
Can immunotherapy be combined with chemotherapy?
Yes. In selected cancers, types of immunotherapy may be combined with chemotherapy or other treatments when clinical evidence supports the approach.
Combined treatment: Different therapies can work through different mechanisms.
Individual planning: The combination, sequence and duration depend on the specific cancer and treatment objective.
Published on Oct 09, 2026 • 9 min read
